Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Zai Lab Ltd ( (HK:9688) ).
Zai Lab Limited announced that it has filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 with the U.S. Securities and Exchange Commission, in line with its obligations as a dual-listed company. The filing underscores the company’s ongoing compliance with U.S. and Hong Kong regulatory requirements and provides investors with updated financial and operational disclosures accessible via the SEC and company websites.
The board also confirmed its current composition, led by Chairperson and Chief Executive Officer Samantha Du and supported by a slate of independent directors with international experience. This governance structure highlights Zai Lab’s focus on maintaining robust oversight and transparency as it navigates global capital markets and advances its biopharmaceutical business strategy.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong, with principal executive offices in Shanghai and Cambridge, Massachusetts. The company operates in the healthcare and life sciences industry, focusing on developing and commercializing innovative medicines for patients in China and global markets.
Average Trading Volume: 10,778,890
Technical Sentiment Signal: Sell
Current Market Cap: HK$18.31B
Learn more about 9688 stock on TipRanks’ Stock Analysis page.